This review highlights copper complexes as therapeutic and diagnostic agents, suggesting their promising potential in overcoming platinum drug limitations.
Copper based metal-organic complexes have been evaluated for their suitability as potential therapeutic and diagnostic agents as an attempt to overcome the limitations of the initial platinum-based drugs, including low selectivity, acquired resistance to the introduced drugs and the subsequent side effects. Copper containing complexes, particularly with tridentate NNN coordinating ligands having polypyridyl groups, such as 2,2'-Dipicolylamine and 2,2':6,2"-Terpyridine, are promising alternatives as they entail versatility in their structures and possess chemical and electronic properties which facilitate their targeted cytotoxic and diagnostic activities. Delocalization of excited electrons within the planar, conjugated structures, along with the display of metal to ligand charge transfer transitions (MLCT) leading to intense fluorescent signals, have elevated the suitability of these ligands for the synthesis of biologically beneficial complexes. This itinerary contributes to the popular global trend in the development of more effective chemotherapeutic and theranostic agents.
No takes yet. Share an insight, caveat, or question.
Wevitavidana et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: